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A. Mansilha,1* F. Arau´jo,2 M. Severo,3 S.M. Sampaio,1 T. Toledo1 and R. Albuquerque1Departments of 1Vascular Surgery, 2Transfusion Medicine and Blood Bank, Molecular Biology Centre, and
3Hygiene and Epidemiology, S. Joa˜o University Hospital, Porto, PortugalObjective. To determine the incidence of deep venous thrombosis (DVT) recurrence in young people, and its association
with some genetic polymorphisms (FV G1691A, FII G20210A, MTHFR C677T, PAI-1 4G/5G).
Design. Prospective cohort study.
Methods. A database was established prospectively to follow-up a cohort of unselected patients who had had a first episode of
objectively proven DVT under the age of 40 years. All patients had DNA analysis for heritable thrombophilia. We excluded
patients with deficiency of antithrombin, protein C or protein S, malignant disease, antiphospholipid syndrome, or a
requirement for long-term antithrombotic treatment. The end-point was objective evidence of symptomatic DVT recurrence.
Results. Eighty-seven patients were enrolled in the study. Mean duration of follow-up was 4.07 years. At 2 years, the
cumulative recurrence rate was 19.3%. The risk of risk was not related to presence or absence of laboratory evidence of
genetic polymorphisms: FV G1619A (HR 1.26 [95%CI: 0.64–2.46]; pZ0.51), FII G20210A (HR 0.81 [95%CI: 0.35–1.89];
pZ0.62), MTHFR C677T (HR 1.26 [95%CI: 0.56–2.81]; pZ0.58), PAI-1 4G/5G (0.84 [95%CI: 0.35–2.05]; pZ0.71).
Conclusion. In this study, the risk of recurrent deep venous thrombosis in young people was not related with the presence of
FV G1691A, FII G20210A, MTHFR C677T or PAI-1 4G/5G polymorphisms.Keywords: Venous thrombosis; Thrombophilia; Genetic polymorphism; Recurrence.Introduction
Patients who have suffered symptomatic deep vein
thrombosis (DVT) remain at risk for recurrent venous
thromboembolism despite adequate anticoagulation
treatment.1 After a first episode of DVT, patients are
usually treated with oral anticoagulation for 6 weeks
to 6 months.2 When treatment is stopped, the
frequency of recurrence can be 12–18% after 2
years.3,4 Of these patients, approximately 5% die
from pulmonary embolism. The risk of recurrence is
highest soon after the acute episode and it declines
with time. Continued treatment with oral anticoagula-
tion therapy will prevent most episodes of recurrence
but there is a substantial risk of major bleeding
associated with prolonged treatment.5,6 In theory,
anticoagulant treatment should be continued until
the risk outweighs the benefit. However, the optimum
duration of treatment is uncertain because the risk of
bleeding associated with anticoagulation and the risk
of recurrent DVT after stopping treatment are noting author. Armando Mansilha, MD, FEBVS, Rua
571, 91 A, 4150-049 Porto, Portugal.
: mansilha@netcabo.pt
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thrombophilic defects, particularly some genetic
polymorphisms, are identified in many patients with
acute DVT.7,8 Data concerning the influence of these on
the risk of recurrent DVT are controversial owing to
the different study designs and patient cohorts which
have been examined.9–17 In this prospective cohort
study, we aimed to determine the incidence of DVT
recurrence in young people, and its association with
some genetic polymorphisms: Factor V Leiden (FV
G1691A), prothrombin G20210A mutation (FII
G20210A), C677T mutation in the 5,10-methylenete-
trahydrofolate reductase gene (MTHFR C677T) and
4G/5G sequence polymorphism in the promoter of
plasminogen activator inhibitor-1 gene (PAI-1 4G/5G).Materials and MethodsInception cohort
All outpatients who were referred to S. Joa˜o University
Hospital, between October 1997 and November 2002,Eur J Vasc Endovasc Surg 30, 545–549 (2005)
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A. Mansilha et al.546because of a first episode of objectively confirmed DVT
under the age of 40 years, were registered on a clinical
outcome audit database (Oporto thrombophilia
study—PORtromb project). Of the 99 consecutive
young patients with a first episode of proven DVT,
12 were excluded from the study. Reasons for
exclusion were malignant disease (nZ1), antipho-
spholipid syndrome (nZ4), deficiency of antithrom-
bin, protein C or protein S (nZ6), need for long-term
treatment with antithrombotic drugs (nZ1). No
patient died or was lost to follow-up. Thus, there
were 87 (88%) patients available for final analysis.
Mean age in this cohort was 27 years (range 16–40) and
58 (67%) were women. The distribution of the initial
thrombotic events in the cohort was: Proximal leg vein,
71 (82%); calf vein, 10 (11%) and arm vein, 6 (7%).
Patients were questioned regarding the circum-
stances under which they experienced their first DVT.
Surgery, trauma, temporary immobilization, contra-
ceptive oestrogen pills and pregnancy were con-
sidered as temporary causes associated with DVT
and in all other patients the DVT episode was defined
as idiopathic or due to a permanent risk factor. We
found 34 patients (39.1%) with idiophatic presentation
and 53 secondary to known risk factors (60.9%).
Thrombophilia testing was offered to all patients
after informed consent. All 87 patients were geno-
typed for FV G1691A, FII G20210A and MTHFR
C677T. Seventy-one (82%) of these were also geno-
typed for PAI-1 4G/5G.
Patients were told the test results might help to
explain why they had suffered venous thrombosis, but
that results might not affect their subsequent
treatment.
All included patients were Caucasians and came
from the same geographical area, the North of
Portugal.
The study protocol was approved by the Ethics
Committee of our Hospital.Study design
DVT was objectively confirmed by colour duplex
ultrasonography or contrast venography. Pulmonary
embolism was diagnosed by ventilation-perfusion
lung scanning, CT, or pulmonary angiography.
Patients were treated with therapeutic doses of low-
molecular-weight or unfractionated heparin, Euro-
pean class 2 compression stockings, and warfarin for 6
months (target international normalized ratio—INR, 2.
5; range, 2.0–3.0).
The patients were followed by frequent out-patient
visits (every 6 months), after inclusion. The patientsEur J Vasc Endovasc Surg Vol 30, 11 2005were asked to report immediately if symptoms
suggestive of recurrent DVT developed and in case
of a suspected episode the participating physicians
were instructed to use objective methods for an
appropriate diagnosis according to the criteria in the
study. In all patients, the radiological evidence for
recurrence was reviewed by one investigator who was
unaware of the results of the thrombophilia tests.
All patients were told their results and advised
regarding acquired risks for DVT and the need for
short-term antithrombotic prophylaxis at times of high
risk. All women were strongly discouraged from using
contraceptive pills regardless of whether they had a
history of an association between the use of these
hormones and the initial episode of DVT.Laboratory methods
EDTA-anticoagulated blood samples from patients
were obtained by venepuncture of the antecubital vein
and frozen immediately after collection. The samples
were stored at K70 8C until assayed. Technicians
unaware of the patients’ clinical diagnosis performed
the tests in a certified laboratory (ISO 9002, EN 45001),
included in external quality assessment schemes (UK
NEQAS and ECAT).
DNA was extracted using QIAamp (Hilden,
Germany) and polymerase chain reaction (PCR) real-
time using LightCyclere (Roche Molecular Biochemi-
cals, Manheim, Germany) was applied. Hybridization
probes technique (sequence-specific fluorescent detec-
tion with oligonucleotide hybridization probes that are
coupled to suitable fluorophores) was used. PCRs
were performed in the LightCycler glass capillaries.
For the Factor V Leiden (G1691A), prothrombin
G20210A mutation and MTHFR C677T, commercial
kits (Roche) were used according to the manufac-
turer’s instructions.
For the PAI-1 polymorphism two mixes, one for
each purpose, were constituted: 2 ml genomic DNA
(100 ng), 10.8 ml H2O, 1.6 ml MgCl2 (3 mM), 1 ml of each
primer (10 mmol), 0.8 ml of each probe (5 mmol) and 2 ml
DNA-Master hybridization probes. The oligonucleo-
tide primers and probes18 were synthesised by TIB
MOLBIOL (Berlin, Germany). The wild-type comp-
lementary detection probes 3 0-labelled with fluor-
escein covered the mutation site (sensor) and the
adjacent anchor probes were 5 0-labelled with the LC-
Red640 dye (anchor). Cycling conditions included
initial denaturation (95 8C for 600 s), followed by 45
cycles with denaturation at 95 8C for 0 s, hybridization
at 59 8C for 5 s and extension at 72 8C for 2 s. Melting
curves were generated by slowly heating the sample to
Table 1. Genetic polymorphisms and risk of recurrence
Polymorphism Patients HR (95%CI) p
FV G1619A* 18/87 1.26 [0.64–2.46] 0.51
FII G20210A† 8/87 0.81 [0.35–1.89] 0.62
MTHFR C677T‡ 9/87 1.26 [0.56–2.81] 0.58
PAI-1 4G/5G§ 20/71 0.84 [0.35–2.05] 0.71
Genetic Polymorphisms and Recurrent DVT 54775 8C. The melting points of the two alleles were at 59
and 65 8C. In different runs, the positions and
distances of the melting peaks were identical and
differed by less than 1 8C for the same allele. For a
better discrimination of heterozygotes, the amplified
products were run on agarose gel.* One homozygote and 17 heterozygotes.
† All heterozygotes.
‡ Only homozygous 677TT were included.
§ Only homozygous 4G/4G were included.Statistical analysis
Time-to-event analysis was done with Kaplan–Meier
curves and compared by a log-rank test. Univariate
and multivariate Cox proportional hazards models
were used to assess the association between DVT
recurrence and genetic polymorphisms, determining
the hazard ratios (HR) and their 95% confidence
intervals (95%CI). A p-value !0.05 was considered
statistically significant.
All computations were performed with the use of
SPSSw software, version 12.0.Results
Two years of follow-up was completed in 75 patients
(86.2%) and mean duration of follow-up was 4.07
years. For the total cohort the cumulative recurrence
rate was 19.3% (standard error 0.045) at 2 years and 23.
2% (standard error 0.051) at 4 years, by Kaplan–Meier
analysis (Fig. 1). Most of the recurrences were in the
leg involved in first episode (63%). Table 1 shows the
risk of recurrent DVT in relation to presence or absence
of laboratory evidence of a heritable defect. When we
analysed the impact of the presence or absence of theFig. 1. Estimated freedom from recurrent deep venous
thrombosis (dotted line—standard errorR10%).FV G1619A mutation, there was no evidence of a
significant difference (HR 1.26 [95%CI: 0.64–2.46]; pZ
0.51). Likewise, when we investigated the FII G20210A
mutation, we noted no evidence of a difference
between carriers and non-carriers (HR 0.81 [95%CI:
0.35–1.89]; pZ0.62). The same results are obtained for
presence or absence of the C677T mutation in the
MTHFR gene, even when only the homozygous
mutant genotype was considered (HR 1.26 [95%CI:
0.56–2.81]; pZ0.58), or for presence or absence of the
PAI-1 4G/5G polymorphism in homozygous 4G state
(HR 0.84 [95%CI: 0.35–2.05]; pZ0.71).
The risk of pulmonary embolism was not signifi-
cantly different between carriers and non-carriers of
these genetic polymorphisms.Discussion
The pathogenesis of a first episode of DVT and of its
recurrence is multifactorial, depending on the severity
and number of hereditary and circumstantial factors.17
The risk of recurrent venous thrombosis is greatly
increased among patients who have had more than
one thromboembolic episode or with an idiopathic
first DVT.1,3,4,6 Debate continues about the use of
testing for evidence of thrombophilia; however, as
results of more studies are reported, the value and
indications for such testing becomes more controver-
sial.19,20
The results of our prospective study show that
young patients with DVT who are heterozygous
carriers of the prothrombin or factor V gene mutation,
or homozygous carriers of the MTHFR C677T or PAI-1
4G/5G polymorphism, are not at higher risk for
further venous thrombotic complications than patients
without a known thrombophilic condition. We believe
than this cohort is representative of young patients
presenting with DVT for whom the optimum duration
of anticoagulation is uncertain. In fact, only patients
with a first episode of symptomatic DVT without
conditions confounding the risk for recurrences were
prospectively enrolled and treated withEur J Vasc Endovasc Surg Vol 30, 11 2005
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bias was avoided by having the adjudication of
recurrent events and genetic testing performed by
operators unaware of other patient details. Patients
were not selected on the basis of family history of
thrombosis, but rather from a cohort of unselected
young patients from which those with malignant
disease, antiphospholipid syndrome or deficiency of
a natural anticoagulant (antithrombin, protein C or
protein S) had been excluded. The overall cumulative
recurrence rate of 19.3% at 2 years, is similar to other
reports.3,4,21 The incidence of thrombophilic defects
(the frequency of the factor V Leiden and FII G20210A
gene mutations was 20.7 and 9.2%, respectively) also
suggests that this cohort is typical of an unselected
patient group.9–13 Another important argument is that
incidence of recurrent DVT is highly dependent on the
extension of the initial thrombosis and we have 82% of
enrolled patients with proximal-vein thrombosis.13
One advantage of this study is the genetically
homogenous sample used, living in the same geo-
graphical area of Portugal. This might be important
due to prevalence variability of these polymorphisms
in different populations.
Because of the small size of the sample only one
patient carried the FV Leiden mutation in homozy-
gous state and none of the patients was homozygotic
for prothrombin gene mutation. These facts precluded
an adequate analysis in the context of homozygosity
for these two mutations.
Our findings are in keeping with the results of other
studies in patients with a first episode of DVT, despite
the singularity of a cohort of young patients.6,9,12,14–17
In contrast, in other reports, an association was found
between the presence of the factor V or prothrombin
gene mutation and recurrent DVT.10,11,13 What could
explain these contradictory findings? Several import-
ant design features can influence the ability of a
clinical study to detect differences in prognosis in
subgroups of patients with venous thrombosis. These
include prospective or retrospective conduct of clinical
follow-up, formation of a proper inception cohort,
duration of treatment between groups, adequate
documentation of outcome events, and independent
assessment of laboratory tests and clinical outcomes.
Retrospective studies have the potential to be unreli-
able because numerous biases may apply, including
inadequate identification of recurrent thrombotic
events, differences in treatment exposure, and patient
selection. Because anticoagulant therapy is highly
effective in preventing recurrent thrombotic events,
differences in exposure between patients with and
without the gene mutations could lead to false
estimations of the risk for recurrence. AdequateEur J Vasc Endovasc Surg Vol 30, 11 2005documentation of venous thrombosis, not only at
baseline but also during follow-up in case of a
suspected recurrent episode, is crucial because clinical
diagnosis is highly unspecific.
We believe that other co-existing and unrecognized
hereditary or acquired conditions predisposing for
recurrent DVT may overshadow the risk generated by
these mutations, which may explain the apparent
discrepancy of the risks for the first and subsequent
episodes of DVT among heterozygotes carriers of the
mutations in the FV and prothrombin genes.
We also believe that an optimal duration and
intensity of the secondary prophylaxis should be
based on the outcome of the coagulation investigation
in combination with clinical information available for
the individual patient. Therefore, more and larger
prospective studies are needed to evaluate the benefit-
to-risk ratio of different durations of anticoagulation.Acknowledgements
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